Company intelligence / Profile preview

Lavima Fertility

Wilmington, Delaware, USAlavimafertility.com ↗

Ownership: Private
Development stage: Commercial

Overview

CAPA-IVM technology has been used to treat several thousand patients in Asian countries and Australia, with more than 850 babies born after CAPA-IVM cycles. A study published in Human Reproduction showed no developmental delays in children conceived using CAPA-IVM compared to those born through conventional IVF[6].

Therapeutic areas: OncologyWomen's Health
Modalities: In vitro maturation (IVM) technology
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

CAPA-IVM

Commercial

Indications: Female infertility, Fertility preservation

Partnerships

IVI RMA Global

Beyond the preview

Go deeper on Lavima Fertility.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lavima Fertility.

Explore the full profile